Home / Psoriasis / Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Brief Summary:
This is a phase II study to evaluate the efficacy and safety of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.

Condition or disease Intervention/treatment Phase
Mild to Moderate Psoriasis Drug: Icotinib hydrochloride cream Drug: Placebo cream Phase 2

Detailed Description:
Icotinib Hydrochloride is an oral, small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which has been approved for treating advanced non-small cell lung cancer (NSCLC) in China. Over-expressions of EGFR and its downstream signaling proteins are implicated in the pathogenesis of psoriasis and TKIs have been considered as potential antipsoriatic agents. Icotinib hydrochloride is being developed as a cream for the treatment of mild to moderate psoriasis. This is a multicenter , randomized, doubleblind, four-arm parallel-group, placebo-controlled phase II study to assess the efficacy and safety of icotinib hydrochloride cream (1.0%, 2.0%, 4.0%) in patients with mild to moderate psoriasis. Approximately 260 subjects will be enrolled.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment :260 participants
Allocation:Randomized
Intervention Model:Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title:A Multicenter, Randomized, Double-blind, Four-Arm Parallel-Group, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
Actual Study Start Date :November 29, 2017
Estimated Primary Completion Date :September 2018
Estimated Study Completion Date :December 2018
Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

U.S. FDA Resources

About

Check Also

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Study Description Go to  Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation. Condition …

Leave a Reply

Your email address will not be published. Required fields are marked *